CLEAR
As a world leader and innovator in biologics for patients with life-threatening and chronic diseases, Amgen is proud to produce biosimilar medicines in pursuit of its mission: to serve patients.
Amgen’s core focus is to discover, develop, and deliver innovative medicines for patients with serious illnesses. We are inspired every day to develop robust therapeutics, from originator biologics to biosimilars.
Amgen’s long-standing commitment to innovation in biotechnology has led to the launch of 18 widely used biologic therapies and a portfolio of 10 biosimilar medicines globally, including potential treatments for cancer, cardiovascular and inflammatory diseases.* This means you can trust us to be a true partner and innovator in biologic medicines, including biosimilars.
*As of August 8, 2019.
Amgen is committed to developing medicines across 6 therapeutic areas
Our four-decade investment in biologics demonstrates an unparalleled experience in researching, developing, and manufacturing medicines, and we are applying that experience to develop biosimilars across multiple therapeutic areas. With investments across 10 biosimilar medicines, you can be sure of our long-term commitment.
We bring high-quality science to the development of biosimilars because of the additional treatment options biosimilars provide to patients, as well as the positive impact they can have on the entire healthcare system.1
At a time when healthcare costs are rising, we aspire to contribute to a more sustainable healthcare system by providing more options and cost savings through our biosimilar medicines.1
With increased availability of lower-cost biosimilars, patients have more options to choose the right medicine at the right time.
There is too much on the line when it comes to life-altering diseases like cancer. That is why we have made it our mission to deliver quality medicines as we strive to meet the needs of patients.
We have been doing it for decades with our originator biologic medicines, and we will maintain that standard with our biosimilars.
Reference: 1. The Center For Biosimilars. Biosimilars market is ripe for cost savings. www.centerforbiosimilars.com/contributor/chad-pettit/2019/06/biosimilars-market-is-ripe-for-cost-savings. Accessed April 17, 2020.